Microbiome Control · Bacteriophage portfolio

PHAGIX™ Line — nature's precision weapon.

Targeted lysis. Self-amplifying. Residue-free.

A bacteriophage platform for poultry, swine, and aquaculture pathogen control. PHAGIX™ harnesses naturally occurring bacteriophages — viruses that infect and lyse specific gut pathogens — while sparing beneficial microbiota. Antibiotic-free, residue-free, and resistance-proof.

Request datasheet The 9 products Published trials

Multi-strain bacteriophage cocktail
1×10⁹ PFU/g powder · 1×10¹⁰ PFU/mL liquid

pH stability 4–11Crop & gizzard active

Heat stability >85% @ 80 °C10 min retention

Storage stability 85.8% @ 360 dAmbient survival

Compatibility Probiotics · enzymes · acidsNo stability impact

Why phages — three things antibiotics can't do.

Bacteriophages are viruses that infect and destroy bacteria. Discovered in 1915, suppressed by the rise of broad-spectrum antibiotics, and now back at the front of the microbiome conversation as antibiotic resistance reshapes commercial animal production. They do three things antibiotics fundamentally cannot.

Targetedlysis

Surgical precision

Phages destroy only what you target

Each phage attacks a specific bacterial genotype. Beneficial microbiota — Lactobacillus, Bifidobacterium, and the rest of the gut ecology — are untouched. Broad-spectrum antibiotics flatten everything.

Self-amplifying

In-house efficacy

Each killed pathogen releases more phages

Phages replicate inside the host bacterium. The product compounds in-vivo: more pathogens lysed means more phages released, until the target population collapses. No equivalent in chemistry.

Residue-free

Zero withdrawal

Degrade naturally after the kill

Phages break down once the target is gone. No residues in meat, eggs, or milk. No withdrawal period. Compatible with antibiotic-free (RWA), organic, and EU-aligned regulatory frameworks.

The PHAGIX™ Line — nine products, three species categories.

PHAGIX™ FORTE is the category umbrella for poultry blends: FORTE P (standard) and FORTE P2 (high-challenge). PHAGIX™ VIBRA serves aquaculture. Three single-pathogen products in development target specific commercial threats — Salmonella, E. coli, and Clostridium perfringens — for situations where the formulator wants surgical control.

Commercial · Poultry & livestock

P™

PHAGIX™ FORTE P

Multi-pathogen poultry cocktail + probiotics

The standard FORTE-family blend for poultry. Composite bacteriophage cocktail targeting E. coli, Salmonella spp., and Clostridium perfringens, formulated with select probiotics for dual-action gut control. Designed for broilers, layers, breeders. Field-validated through three published trials.

E. coli Salmonella C. perfringens + probiotics

200 g/MT standard poultry inclusion · 400–500 g/MT swine

Concentrate · Feed manufacturers

P2™

PHAGIX™ FORTE P2

High-titer concentrate · no probiotic carrier

The raw-material concentrate version of FORTE P. Higher titer per gram, no probiotic carrier — designed for feed manufacturers and integrators who blend proprietary premixes. E. coli (6×10⁹ PFU/g) · Salmonella (3.5×10¹⁰ PFU/g) · C. perfringens (2×10⁹ PFU/g) phage actives only.

E. coli Salmonella C. perfringens No probiotic carrier

20 g/MT feed · 10 g / 1,000 L drinking water

Commercial · Aquaculture

PHAGIX™ VIBRA FORTE

Multivalent Vibrio cocktail · shrimp aquaculture

Multivalent bacteriophage complex targeting V. parahaemolyticus (AHPND/EMS), V. alginolyticus, and V. harveyi. In vitro lytic activity validated against aquaculture reference strains (Komipharm, South Korea). Applied via feed or water across larvae, post-larvae, and grow-out stages.

AHPND control Vibrio spp. Powder + liquid

100–200 g per 100–120 kg feed · 5–30 ppm water treatment

In development

PHAGIX™ FORTE C

Composite cocktail + probiotics · swine

Finished-good feed additive for swine, combining bacteriophage against E. coli, Salmonella and Clostridium perfringens at 1×10⁹ PFU/g with probiotics. The swine counterpart to the FORTE poultry composites, applied through feed or water.

E. coli · Salmonella · C. perfringens + Probiotics Swine

500 g per tonne · feed or water

In development

PHAGIX™ FORTE SP

Cocktail blend + named probiotic strains · poultry

Cocktail blend targeting E. coli, Salmonella and Clostridium perfringens at 2×10⁷ PFU/g, formulated with Bacillus licheniformis, Bacillus subtilis and Lactobacillus plantarum. Named probiotic strains rather than a generic blend.

E. coli · Salmonella · C. perfringens 3 named probiotic strains Poultry

300–500 g per tonne feed

In development

PHAGIX™ VIBRA S

Vibrio finished good · aquatic species

Finished-good bacteriophage targeting V. parahaemolyticus, V. alginolyticus and V. harveyi at 1×10⁹ PFU/g each. The ready-to-apply counterpart to VIBRA FORTE, supplied for direct feed application or water dosing.

Vibrio spp. Finished good Aquatic species

200 g per 20 kg feed · twice daily, 4–7 days

In development

PHAGIX™ SALVAN

Single-pathogen · Salmonella

Targeted control of Salmonella spp. and prevention of Salmonella colonization in the intestine. Designed for integrators with documented Salmonella pressure who want surgical control independent of the broader FORTE composite cocktail.

Single pathogen Salmonella spp.

Specifications & commercial launch — coming soon

In development

PHAGIX™ ECO

Single-pathogen · E. coli

Targets Escherichia coli, improving intestinal health and reducing the salpingitis and diarrhea load that drives layer culls and broiler mortality. Surgical option for E. coli-dominated pressure profiles.

Single pathogen E. coli

Specifications & commercial launch — coming soon

In development

PHAGIX™ CLOSTRA

Single-pathogen · Clostridium perfringens

Targeted control of Clostridium perfringens, the agent of necrotic enteritis. Four internal study formats — feed supplementation, therapy, vaccine candidate, and environmental application — have already demonstrated bacterial-load reductions of 70–90%.

Single pathogen C. perfringens Necrotic enteritis

Specifications & commercial launch — coming soon

Evidence status — mandatory disclosure. The E. coli + Salmonella phage backbone is validated in vivo across three peer-reviewed poultry trials (broilers n=1,500 · layers n=2,400 · Ma-chicken n=1,050). The C. perfringens phage component in FORTE P and FORTE P2 is platform-supported — in vitro lytic activity confirmed; a confirmatory field trial is planned. VIBRA FORTE has validated in vitro lytic activity against Vibrio aquaculture pathogens (Komipharm, South Korea); in vivo aquaculture field trial data is being accumulated through ongoing commercial programs.

Published trials — three peer-reviewed studies.

PHAGIX™ FORTE P has been validated in three published animal-science studies — white-feather broilers, Hy-Line Brown layers, and Guangxi Ma-chickens — published in Chinese veterinary research journals with full DOI references and authorized English translations on file.

White-feather broilers · growth, gut flora, immunity

Published study · April 2020 1,500 day-old broilers · 42 days · Linyi, Shandong

Design. 5 treatments × 10 replicates × 30 birds. Control vs antibiotic (Nosihepde 300 g/t + Chlortetracycline 200 g/t) vs PHAGIX™ FORTE P at 100, 200, and 500 g/t. Endpoints: growth performance, diarrhea, mortality, cecal microflora, immune organ indices, serum IgA/IgG/IgM.

Parameter	Control	Antibiotic	PHAGIX™ FORTE P 200 g/t (recommended)
F/G (feed-to-gain)	1.63	1.52	1.51 · −7.36%
ADG (g/bird·d)	65.37	71.85	72.39 · +5.31%
Diarrhea rate (%)	18.67	6.33	5.67
Mortality rate (%)	9.67	5.33	4.33
E. coli (log CFU/g)	6.77	6.01	5.38
Salmonella (log CFU/g)	4.87	4.66	3.38
Lactic acid bacteria (log CFU/g)	7.52	6.63	8.23
Serum IgG (g/L)	6.72	6.65	7.56

Recommended dose: 200 g/t PHAGIX™ FORTE. Notable outcome: phage reduced both pathogens AND lifted beneficial Lactobacillus — antibiotic suppressed Lactobacillus (6.63 vs 7.52 control). DOI: 10.13557/j.cnki.issn1002-2813.2020.04.029

Hy-Line Brown layers · production performance & egg quality

Published study · July 2020 2,400 layers @ 50 wks · 30 days · Handan, Hebei

Design. 4 treatments × 6 replicates × 100 birds. Control vs PHAGIX™ FORTE P at 100, 300, and 500 g/t. Endpoints: laying rate, egg weight, FCR, defective egg rate, Haugh unit, shell quality, intestinal microflora.

Parameter	Control	PHAGIX™ FORTE P 300 g/t (recommended)	Δ vs control
Laying rate (%)	90.35	92.56	+2.45%
FCR (feed:egg)	2.22	2.11	−4.95%
Defective egg rate (%)	2.51	1.07	−57.37%
Haugh unit	86.76	90.19	+3.95%
E. coli (log CFU/g)	6.87	5.51	Significant ↓
Salmonella (log CFU/g)	4.77	3.55	Significant ↓

Recommended dose: 300 g/t. Standout finding: defective egg rate cut by more than half — meaningful for layer programs where shell quality drives downstream revenue. DOI: 10.13557/j.cnki.issn1002-2813.2020.07.031

Guangxi Ma-chicken · phage + antimicrobial peptide combinations

Published study · July 2022 1,050 birds @ 35 days · 35-day trial

Design. 7 treatments × 5 replicates × 30 birds. Combinations of PHAGIX™ FORTE P (50, 100, 150, 300 mg/kg) with antimicrobial peptide (AMP). Endpoints: ADG, F/G, diarrhea, mortality, gut microflora, immune organs.

Group	F/G	Diarrhea (%)	Mortality (%)	Outcome
Control	2.62	9.33	8.67	Baseline
PHAGIX™ alone · 300 mg/kg	2.51	4.00	5.33	−4.20% F/G
PHAGIX™ + AMP · 300/300 mg/kg	2.49	3.33	4.00	−4.96% F/G · lowest mortality
PHAGIX™ + AMP · 100/100 mg/kg	2.52	4.67	4.67	Recommended · best cost-efficacy

Recommended dose: 100 mg/kg PHAGIX™ + 100 mg/kg antimicrobial peptide — best balance of efficacy and cost. Mechanism note: phage and AMP work synergistically — phage suppresses pathogen, AMP supports immune response. DOI: 10.13557/j.cnki.issn1002-2813.2022.07.024

Aquaculture — PHAGIX™ VIBRA FORTE against Vibrio.

Vibrio outbreaks drive most shrimp-farming losses, particularly AHPND (Acute Hepatopancreatic Necrosis Disease). Antibiotics are widely banned. PHAGIX™ VIBRA delivers stage-specific phage protection across the production cycle — Mysis, Larvae, Post-larvae, and Adult.

12h

Larvae stage eradication

30 ppm phage · Vibrio eradicated

89.7%

Adult stage reduction

10 ppm phage · 17 hours

All stages

Mysis · Larvae · Post-larvae · Adult

Stage-specific dosing schedule

Stage-specific dosing & outcomes

Stage	Phage dose	Outcome
Mysis	5 ppm	Improved appetite & feed intake
Larvae	30 ppm	Vibrio eradicated within 12 hours
Post-larvae	5 ppm	Vibrio reduced in 25 m³ tanks
Adult	10 ppm	Vibrio reduced up to 89.7% in 17 hours

Source: KYNAD aquaculture program data and Komipharm International Co., Ltd. in vitro validation (Siheung, South Korea). The Komipharm assay confirmed in vitro lytic activity (7/7 isolates, confluent lysis through 10⁹ dilution) against aquaculture reference strains. Commercial program outcomes vary by water quality, stocking density, and regional Vibrio strain profile. In vivo aquaculture field trial data is being accumulated through ongoing commercial programs.

Clostridium control — previewing PHAGIX™ CLOSTRA.

Four study formats have already characterized PHAGIX phage activity against Clostridium perfringens — the agent of necrotic enteritis. Bacterial-load reductions of 70–90% across feed, therapy, and environmental application. These trials inform the upcoming PHAGIX™ CLOSTRA single-pathogen product.

80%

Therapy · bacterial-load reduction

Necrotic enteritis treatment trial
(vs antibiotic 75%, placebo 0%)

70%

Feed supplementation · fecal reduction

200 broilers · 30 days
(infection rate 12% vs 35% control)

60%

Vaccine candidate · antibody increase

Phage-protein subunit
(infection 15% vs 45% control)

90%

Environmental application · floor/water

10,000 birds · sprayed q3 days, 2 wks
(25% infection rate reduction)

Therapy trial · phage vs antibiotic head-to-head

Bacteriophage therapy for necrotic enteritis

KYNAD trial 100 day-old broilers · 7 days oral phage
vs tylosin (antibiotic) vs placebo

Design. Broilers inoculated with C. perfringens strain (A) to induce necrotic enteritis. Three arms: PHAGIX™ phage (10⁹ PFU/mL in drinking water, 7 days), tylosin antibiotic, saline placebo.

Endpoint	Placebo	Antibiotic (Tylosin)	PHAGIX™ phage
C. perfringens reduction	No reduction	75%	80%
Mortality rate	30%	25%	5%
Clinical signs (diarrhea, lethargy)	Severe	Reduced	Significantly reduced

Source: KYNAD Clostridium bacteriophage poultry trial dossier. Field application case studies from Shandong, Rizhao, and Henan poultry operations also on file. PHAGIX™ CLOSTRA single-pathogen specifications and commercial dosing to follow product launch.

Technical specifications.

Core PHAGIX™ chemistry across the line. Product-specific certificates of analysis available on request for PHAGIX™ FORTE and PHAGIX™ VIBRA. SALVAN, ECO, and CLOSTRA specifications publish at commercial launch.

Active ingredient	Multi-strain bacteriophage cocktail · target-specific lytic phages
Formulation	Powder: 1×10⁹ PFU/g · Liquid: 1×10¹⁰ PFU/mL
pH stability	Active across pH 4–11 (crop, gizzard, and small intestine)
Heat stability	>85% activity retained after 10 minutes at 80 °C · stable to 85 °C pelleting
Storage stability	85.8% survival rate after 360 days · 24 months at <25 °C, retains >90% activity
Compatibility	Safe with probiotics, enzymes, organic acids — no impact on vitamin, mineral, or enzyme stability
Species coverage	Broilers, layers, breeders · adaptable to turkeys, swine, ruminants, aquaculture
Dosage accuracy	Validated analytical methods for consistent delivery
Storage conditions	Cool, dry place 5–25 °C · away from direct sunlight · liquid 2–8 °C · reseal after opening
Shelf life	12 months from manufacture (24 months for powder under optimal conditions)
Package formats	1 kg easy-tear sachets · 10 kg & 25 kg resealable bags · bulk totes on request
Handling	No refrigeration required (powder) · dust-free formulation · standard feed-additive PPE

Quality assurance.

Phage titer 1×10⁹ PFU/gPer batch release

pH active 4–11Full gut coverage

Pellet recovery >85% @ 80°C10-min retention

Long-term 85.8% @ 360 dAmbient stability

Dosing method Validated methodConsistent delivery

Dosing Matrix — by product & species.

Field-validated dosing for both commercial products. Single-pathogen product dosing will publish at commercial launch. KYNAD technical team provides custom recommendations for pathogen pressure profiles and feed format.

Product	Application	Recommended dose
PHAGIX™ FORTE P	Poultry · broilers (cycle range)	200–500 g/MT
PHAGIX™ FORTE P	Poultry · broilers (recommended optimum)	200 g/MT
PHAGIX™ FORTE P	Poultry · layers	300 g/MT
PHAGIX™ FORTE P2	Poultry · feed manufacturers & integrators (feed)	20 g/MT feed
PHAGIX™ FORTE P2	Poultry · feed manufacturers & integrators (water)	10 g / 1,000 L water
PHAGIX™ FORTE P	Swine	400–500 g/MT
PHAGIX™ VIBRA	Aquaculture · prevention (powder feed)	100–200 g per 100–120 kg feed
PHAGIX™ VIBRA	Aquaculture · prevention (liquid feed)	200 g per 40–60 kg feed
PHAGIX™ VIBRA	Aquaculture · treatment (powder)	5–10 ppm water
PHAGIX™ VIBRA	Aquaculture · treatment (liquid splash/feed)	10–30 ppm
PHAGIX™ SALVAN/ECO/CLOSTRA	Single-pathogen specifications publish at commercial launch

Request

Request the full PHAGIX™ packet.

Product overviews for PHAGIX™ FORTE & PHAGIX™ VIBRA, the Bacteriophage Portfolio Introduction Book (28-page deck), three published peer-reviewed studies with authorized translations, and the Clostridium bacteriophage trial dossier. Single-pathogen product roadmap available on request.

Request packet Microbiome Control